Bibliometric Analysis of Colistin-Related Theses in Türkiye

Abstract

Objective In recent years, due to the limited number of novel antibiotics and the developing resistance to existing ones have become significant challenges. Colistin, an antibiotic known for its efficacy against some gram-negative bacteria especially Acinetobacter spp. and Klebsiella spp., was previously restricted due to its adverse effects, has reintroduced into clinical practice as a last-resort treatment option. In this study, it was aimed to conduct a bibliometric analysis of the thesis studies on colistin in Turkey. Methods In this descriptive study, a search was made on the database of the National Thesis Center of the Council of Higher Education of Turkey, which includes theses written in Turkey, on December 10, 2024, using the keyword "colistin". 121 theses identified as a result of the screening were included in the study without applying any exclusion criteria. The data obtained are presented as numbers and percentages. Results It was determined that the majority of the studies were medical specialty theses. There has been an increase in the number of theses on colistin over the years, and the most studies were conducted in 2021. Most studies were conducted in the fields of Microbiology and Clinical Microbiology and Infectious Diseases. The studies focused not only on the efficacy of colistin but also on resistance mechanisms and side effect profiles. Among the 15 studies that specifically evaluated nephrotoxicity in human subjects, an average nephrotoxicity rate of 50% was reported. Conclusion This study reveals the growing academic interest and research trends regarding colistin in Türkiye. The findings show that as colistin re-enters clinical practice, its place in the scientific literature is strengthened. Further research on colistin’s efficacy and adverse effect profile is essential to provide comprehensive insights for its clinical use.

Keywords

• Bibliometrics
• Colistin
• Nephrotoxicity

References

1. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589-601. doi:10.1016/S1473-3099(06)70580-1.
2. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535-543. doi:10.1097/QCO.0b013e328332e672.
3. El-Sayed Ahmed MAEG, Zhong LL, Shen C, et al. Colistin and its role in the era of antibiotic resistance: an extended review (2000–2019). Emerg Microbes Infect. 2020;9:868–885. doi:10.1080/22221751.2020.1754133.
4. Bostanghadiri N, Narimisa N, Mirshekar M, et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2024;13(1):24. doi:10.1186/s13756-024-01376-7.
5. Mirjalili M, Mirzaei E, Vazin A. Pharmacological agents for the prevention of colistin-induced nephrotoxicity. Eur J Med Res. 2022;27(1):64. doi:10.1186/s40001-022-00689-w.
6. Kalın G. The comparison of colistin and colistin/sulbactam combination therapies for treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Specialty Thesis in Medicine, Clinical Microbiology and Infectious Diseases. Erciyes Üniversitesi; 2013. Kayseri.
7. Özkarakaş H. Nephrotoxicity rates among critically ill patients receiving colistin. Specialty Thesis in Medicine, Anesthesiology and Reanimation. İzmir Tepecik Eğitim Hastanesi; 2014. İzmir.
8. Özel AS. Prospective monitoring of adverse events of colistin treatment in critically ill patients after implementation of a new dosing strategy. Specialty Thesis in Medicine, Clinical Microbiology and Infectious Diseases. Marmara University; 2015. İstanbul.

9. Çoşkun B. Assessment of colistin treatment in multi-drug resistant gram-negative bacterial infections. Specialty Thesis in Medicine, Clinical Microbiology and Infectious Diseases. Ankara University; 2015. Ankara.
10. Cantay B. The evaluation of colistin efficacy and safety in preterm infants. Specialty Thesis in Medicine, Child Health and Diseases. Kahramanmaraş Sütçü İmam University; 2016. Kahramanmaraş.
11. Aliyev V. Evaluation of efficacy and safety of low and high dose colistin use in intensive care unit patients who had ventilator-associated pneumonia due to enteric or non-enteric bacteria. Specialty Thesis in Medicine, Clinical Microbiology and Infectious Diseases. İstanbul University; 2016. İstanbul.
12. Dindar Demiray EK. Colymsin treatment effectiveness by loading dose in infections caused by multiresistant gram-negative bacteria. Specialty Thesis in Medicine, Clinical Microbiology and Infectious Diseases. Manisa Celal Bayar University; 2018. Manisa.
13. Moroğlu Ç. Retrospective evaluation of the colistin-related nephrotoxicity rates and effectiveness of vitamin C use to prevent nephrotoxicity. Specialty Thesis in Medicine, Clinical Microbiology and Infectious Diseases. Sağlık Bilimleri University; 2018. İstanbul.
14. Ecemiş S. Monitoring and evaluation of colistin blood level at intensive care units. Pharmacy and Pharmacology Master's Thesis. Hacettepe University; 2019. Ankara.
15. Keserci Ö. Comparison of ABH development related to the use of colistin in stage 3 intensive care unit according to RIFLE and KDIGO. Specialty Thesis in Medicine, Internal Medicine. Dicle University; 2020. Diyarbakır.
16. Özkaraman Y. Investigation of neutrophil gelatinase-associated lipocalin (NGAL) and liver-type fatty acid binding protein (l-FABP) levels in the urinary for early detection of nephrotoxicity associated with colistin therapy. Specialty Thesis in Medicine, Clinical Microbiology and Infectious Diseases. Sağlık Bilimleri University; 2021. Antalya.
17. Aksoy P. Evaluation of biochemical parameters and intensive care scores in child intensive care patients using colistin. Specialty Thesis in Medicine, Child Health and Diseases. Sağlık Bilimleri University; 2022. İstanbul.
18. Cengiz B. Comparison of KIM-1, NGAL, and IL-18 biomarkers as early markers in prognosis of colistin nephrotoxicity. Specialty Thesis in Medicine, Internal Diseases. Sağlık Bilimleri University; 2022. Ankara.
19. Akça HN. Investigation of the effect of colistin monotherapy and colistin-meropenem combined therapy on mortality in patients with colistin-resistant A. baumannii bacteremia in Ankara City Hospital Intensive Care Unit. Specialty Thesis in Medicine, Clinical Microbiology and Infectious Diseases. Ankara Yıldırım Beyazıt University; 2023. Ankara.
20. Tutar Selçuk MF. Comparison of renal function tests of intensive care unit patients using polymyxin or colistin. Specialty Thesis in Medicine, Internal Diseases. Tekirdağ Namık Kemal University; 2024. Tekirdağ.
21. PubMed. Search for "colistin". National Library of Medicine. Available at: https://pubmed.ncbi.nlm.nih.gov/?term=colistin. Accessed December 21, 2024.
22. Nwabor OF, Terbtothakun P, Voravuthikunchai SP, Chusri S. A bibliometric meta-analysis of colistin resistance in Klebsiella pneumoniae. Diseases. 2021;9(2):44. doi:10.3390/diseases9020044.
23. Yacouba A, Olowo-Okere A. Global trends and current status in colistin resistance research: a bibliometric analysis (1973-2019). F1000Research. 2020 Jul 31;9:856. doi:10.12688/f1000research.25124.1.
24. Sağlık Bilimleri Üniversitesi. Tarihçemiz. Available at: https://sbu.edu.tr/universitemiz/kurumsal-bilgilerimiz/tarihcemiz/. Accessed December 24, 2024.
25. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016 Feb;16(2):161-8. doi:10.1016/S1473-3099(15)00424-7.
26. PubMed. Search for "colistin". National Library of Medicine. Available at: https://pubmed.ncbi.nlm.nih.gov/?term=mcr1+and+colistin. Accessed February 2, 2025.